In this PACULit episode, the topic is the prospective validation of the Childhood Hodgkin International Prognostic Score (CHIPS) in high-risk pediatric Hodgkin lymphoma treated within the AHOD1331 trial. CHIPS, based on stage IV disease, large mediastinal adenopathy, hypoalbuminemia, and fever, independently predicts event-free survival across treatment arms (brentuximab vedotin plus AVEPC versus ABVE-PC) and across PET2 response categories and disease stages. CHIPS distribution was balanced between arms, supporting unbiased validation. The prognostic value persists among PET2 rapid responders and stage IVB patients, highlighting CHIPS as a practical, cost-effective tool to guide risk-adapted therapy and resource allocation, especially where advanced diagnostics are limited. Clinical implications include anticipating toxicities and informing dose-modification decisions, with attention to brentuximab vedotin–related neuropathy and other regimen toxicities. Limitations include generalizability to non-high-risk groups and the absence of novel biomarkers; integration with PET2 remains advisable for refined risk stratification. For full details, see PMID 40515508.
View all episodes
